Literature DB >> 14718524

Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.

Lenin Mahimainathan1, Goutam Ghosh Choudhury.   

Abstract

PTEN, mutated in a variety of human cancers, is a dual specificity protein phosphatase and also possesses D3-phosphoinositide phosphatase activity on phosphatidylinositol 3,4,5-tris-phosphate (PIP(3)), a product of phosphatidylinositol 3-kinase. This PIP(3) phosphatase activity of PTEN contributes to its tumor suppressor function by inhibition of Akt kinase, a direct target of PIP(3). We have recently shown that Akt regulates PDGF-induced DNA synthesis in mesangial cells. In this study, we demonstrate that expression of PTEN in mesangial cells inhibits PDGF-induced Akt activation leading to reduction in PDGF-induced DNA synthesis. As a potential mechanism, we show that PTEN inhibits PDGF-induced protein tyrosine phosphorylation with concomitant dephosphorylation and inactivation of tyrosine phosphorylated and activated PDGF receptor. Recombinant as well as immunopurified PTEN dephosphorylates autophosphorylated PDGF receptor in vitro. Expression of phosphatase deficient mutant of PTEN does not dephosphorylate PDGF-induced tyrosine phosphorylated PDGF receptor. Rather its expression increases tyrosine phosphorylation of PDGF receptor. Furthermore, expression of PTEN attenuated PDGF-induced signal transduction including phosphatidylinositol 3-kinase and Erk1/2 MAPK activities. Our data provide the first evidence that PTEN is physically associated with platelet-derived growth factor (PDGF) receptor and that PDGF causes its dissociation from the receptor. Finally, we show that both the C2 and tail domains of PTEN contribute to binding to the PDGF receptor. These data demonstrate a novel aspect of PTEN function where it acts as an effector for the PDGF receptor function and negatively regulates PDGF receptor activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718524     DOI: 10.1074/jbc.M314328200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs.

Authors:  Anabel Gil; Amparo Andrés-Pons; Elena Fernández; Miguel Valiente; Josema Torres; Javier Cervera; Rafael Pulido
Journal:  Mol Biol Cell       Date:  2006-06-28       Impact factor: 4.138

3.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

4.  PTEN directly activates the actin depolymerization factor cofilin-1 during PGE2-mediated inhibition of phagocytosis of fungi.

Authors:  C Henrique Serezani; Steve Kane; Alexandra I Medeiros; Ashley M Cornett; Sang-Hoon Kim; Mariana Morato Marques; Sang-Pyo Lee; Casey Lewis; Emilie Bourdonnay; Megan N Ballinger; Eric S White; Marc Peters-Golden
Journal:  Sci Signal       Date:  2012-02-07       Impact factor: 8.192

5.  Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency.

Authors:  Zheqing P Cai; Zhenyun Shen; Luc Van Kaer; Lewis C Becker
Journal:  FASEB J       Date:  2008-08-26       Impact factor: 5.191

Review 6.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

7.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

Review 8.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

9.  PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy.

Authors:  Nirmalya Dey; Nandini Ghosh-Choudhury; Falguni Das; Xiaonan Li; Balachandar Venkatesan; Jeffrey L Barnes; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

10.  Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.

Authors:  L Davidson; H Maccario; N M Perera; X Yang; L Spinelli; P Tibarewal; B Glancy; A Gray; C J Weijer; C P Downes; N R Leslie
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.